Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A preliminary study shows that a drug which helps immune cells self-clean may improve vaccine protection in older adults

Syringe containing vaccine © Anna Shvets from Pexels

A drug that boosts the removal of cellular debris in immune cells may increase the protective effects of vaccines in older adults, a study published today in eLife shows.

The results may lead to new approaches to protect older individuals from viruses such as the one causing the current COVID-19 pandemic and influenza.

"Older adults are at high risk of being severely affected by infectious diseases, but unfortunately most vaccines in this age group are less efficient than in younger adults," explains lead author Ghada Alsaleh, a postdoctoral researcher at the Kennedy Institute of Rheumatology, University of Oxford, UK.

Previously, Alsaleh and colleagues showed that in older mice immune cells may become less efficient at removing cellular debris, a process called autophagy, and this leads to a poorer immune response in the animals. In the current study, they looked at samples from young and older people participating in clinical trials for vaccines against the respiratory syncytial virus and the hepatitis C virus to see if the same event happens in human immune cells called T cells. They found that autophagy increases in T cells from younger people after receiving vaccines, but this response is blunted in older people.

When they examined T cells from the older individuals in the laboratory, the team found that these cells have less of a natural compound called spermidine. Spermidine ramps up autophagy and boosts T-cell function. Supplementing these older immune cells with spermidine in the laboratory restored autophagy to the same levels seen in T cells from younger people. "Our work suggests that boosting autophagy during vaccination may help make vaccines more effective for older people," Alsaleh says.

A small clinical trial recently tested whether giving spermidine to older adults would improve their cognitive function. As the results were positive, and spermidine did not appear to have any harmful effects, this provides some evidence that it would be safe to test whether spermidine might also be helpful for boosting the immune response of older people to vaccines.

"Our findings will inform vaccine trials in which autophagy-boosting agents, such as spermidine, are given in a controlled environment to older participants," concludes senior author Anna Katharina Simon, Professor of Immunology at the University of Oxford. "It will be interesting to see whether these agents can enhance vaccination efficiency and help protect older people from viral infections."

Similar stories

Clinical trial finds Azithromycin has no benefit against COVID-19

Main OCTRU

A clinical trial by University of Oxford researchers has confirmed that the antibiotic azithromycin has no clinical benefit in people with moderate COVID-19.

Study reveals the three most important aspects of care for hip fractures

Hip Main OCTRU Research Trauma

Older patients with hip fractures recover better if they receive treatment under the supervision of both a surgeon and a specialist in elderly care; are checked to avoid future falls; and are assessed for memory problems.

Major ERC funding awarded to Professor Michael Dustin

Awards Kennedy Main

Professor Michael Dustin and an international team of collaborators have been awarded a €10M grant from the European Research Council (ERC) to develop a new biotechnology around supramolecular attack particles (SMAPs) engineered to kill cancer cells.

The role of mAbs (neutralising monoclonal antibodies) in the fight against COVID-19

Main Research

Neutralising mAbs, a form of anti-viral medicine, are being explored as an attractive option to treat symptoms of COVID-19 and in some cases prevent infection. But what are the pros and cons of this type of treatment and what should regulators consider before granting approval?

Professor Michael Dustin elected to the National Academy of Sciences

Awards Kennedy Main

Recognised for his outstanding contributions to the field of immunology, Michael becomes the fourth Kennedy professor to be elected to the Academy.

Small mechanical forces in immune cells measured at unprecedented sensitivity

Kennedy Main Research

Oxford researchers have used advanced microscopy techniques to measure previously unseen forces generated by cells during an immune response; a breakthrough for mechanobiology and future advances in health and disease.